LeMaitre Vascular (NASDAQ:LMAT) Reaches New 12-Month High Following Strong Earnings

LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s share price hit a new 52-week high during trading on Thursday following a stronger than expected earnings report. The company traded as high as $112.65 and last traded at $105.6410, with a volume of 191905 shares changing hands. The stock had previously closed at $91.38.

The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The business had revenue of $64.45 million during the quarter, compared to analysts’ expectations of $62.98 million. During the same quarter in the prior year, the business posted $0.49 EPS. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th will be given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.9%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend is Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio is presently 34.48%.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat consensus: GAAP EPS $0.68 vs. $0.67 expected and revenue $64.45M vs. $62.98M expected; revenue rose 15.7% year-over-year — underlying growth and margin strength support the rally. MarketBeat: Earnings Report
• Positive Sentiment: Guidance raised: Q1 FY2026 EPS guide of $0.640–0.690 (above consensus $0.620) and FY2026 EPS $2.810–3.010 (vs. consensus $2.610); revenue guides also above estimates — implies management confident in secular growth. Press Release: FY2026 Guidance
• Positive Sentiment: Dividend increase: quarterly payout raised 25% to $0.25/share (ex-dividend March 12, pay March 26), signaling capital-return discipline and confidence in cash flow — supports investor sentiment.
• Neutral Sentiment: Earnings call and analysis available for details on product/market drivers; investors should review management commentary on procedure volumes and M&A. SA: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Coverage/analysis pieces (e.g., Benzinga) summarize expectations and may influence short-term flows but add no new company facts. Benzinga: Earnings Expectations
• Negative Sentiment: Valuation and yield context: LMAT trades at a relatively rich P/E (~46) and a modest dividend yield (~1.1%), which could limit upside if growth slows or guidance is trimmed in future quarters.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Roth Mkm reiterated a “buy” rating and issued a $108.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Barrington Research reiterated an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Friday, February 20th. Wells Fargo & Company dropped their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. Cantor Fitzgerald restated a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research note on Monday, November 10th. Finally, Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular has a consensus rating of “Hold” and a consensus target price of $103.17.

Institutional Investors Weigh In On LeMaitre Vascular

Several institutional investors have recently modified their holdings of the company. Vest Financial LLC increased its position in LeMaitre Vascular by 60.0% during the third quarter. Vest Financial LLC now owns 56,279 shares of the medical instruments supplier’s stock worth $4,925,000 after buying an additional 21,102 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of LeMaitre Vascular in the third quarter valued at $1,101,000. First Trust Advisors LP boosted its stake in shares of LeMaitre Vascular by 52.7% during the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock valued at $50,829,000 after acquiring an additional 211,280 shares during the last quarter. Envestnet Asset Management Inc. increased its position in LeMaitre Vascular by 6.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock worth $25,293,000 after purchasing an additional 19,447 shares in the last quarter. Finally, Congress Asset Management Co. raised its stake in LeMaitre Vascular by 2.7% in the 3rd quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock valued at $60,580,000 after purchasing an additional 18,298 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

The company has a market capitalization of $2.47 billion, a PE ratio of 46.96, a price-to-earnings-growth ratio of 2.01 and a beta of 0.72. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58. The stock’s fifty day simple moving average is $85.98 and its 200-day simple moving average is $88.12.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.